Effects of nonsteroidal anti-inflammatory drugs, including COX-2 specific inhibitors, on the GI tract

ASGE Clinical Update

Volumn 12, Issue 3, 2005, Pages 1-4

  Scheiman, James M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; IBUPROFEN; KETOROLAC; LANSOPRAZOLE; MELOXICAM; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROSTAGLANDIN; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; SALSALATE;

ABDOMINAL CRAMP; ANALGESIA; ARTICLE; CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLITIS; COLON DISEASE; COST BENEFIT ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM ULCER; DIVERTICULOSIS; DRUG ABSORPTION; DRUG SAFETY; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPY; ENTERITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; HEADACHE; HEALTH SURVEY; HELICOBACTER PYLORI; HUMAN; MORTALITY; PROTEIN EXPRESSION; QUALITY OF LIFE; RISK ASSESSMENT; SMALL INTESTINE DISEASE; STOMACH ABSORPTION; STOMACH HEMORRHAGE; TOXICITY; ULCER;

EID: 27844479351     PISSN: 10707212     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinup.2004.10.001     Document Type: Article

References (19)

1. Scheiman J. NSAIDs, cytoprotection, and gastrointestinal injury. Gastroenterol Clin North Am 25 (1996) 279-298
2. Chan F., Chung S., Suen B., Lee Y., Leung W., Leung V., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344 (2001) 967-973
3. Wallace J., McKnight W., Reuter B., and Vergnolle N. NSAIDS-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119 (2000) 706-714
4. Hayden M., Pignone M., Phillips C., and Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 136 (2002) 161-172
5. Cox E., Frisse M., Behm A., and Fairman K. Over the counter pain reliever and aspirin use within a sample of long-term cyclyooxygenase 2 users. Arch Intern Med 164 (2004) 1243-1245
6. Yeomans N., Tulassay Z., Juhasz L., Racz I., Howard J., van Rensburg C., et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 338 (1998) 719-726
7. Hawkey C., Karrasch J., Szczepanski L., Walker D., Barley N., and Swannel A. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 338 (1998) 727-734
8. Graham D., Agrawal N., Campbell D., Haber M., Collis C., Lukasik N., et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active-and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162 (2002) 169-175
9. Hawkey C., Yeomans N., Jones R., Scheiman J., Langstrom G., Lamm M., et al. Esomeprazole improves quality of life in patients with upper GI symptoms associated with long-term NSAID therapy [abstract]. Gastroenterology 124 (2003) A*107
10. Scheiman J., Yeomans N., Hawkey C., Talley N., Gothe L., Sung J., et al. Esomeprazole reduces gastric and duodenal ulcer development among high risk NSAID users [abstract]. Am J Gastroenterol 989 (2003) S52
11. Deeks J., Smith L., and Bradley M. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. BMJ 325 (2002) 619-626
12. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 20-28
13. Silverstein F., Faich G., Goldstein J., Simon L., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The Class Study: a randomized controlled trial. JAMA 284 (2000) 1247-1255
14. Scheiman J. Gastroduodenal safety of Cox-2 specific inhibitors. Curr Pharm Des 9 (2003) 2197-2206
15. Chan F., Hung L., Suen B., Wu J., Lee K., Leung V., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 (2002) 2104-2110
16. Mamdani M., Juurlink D., Kopp A., Naglie G., Austin P., and Laupacis A. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ 328 (2004) 1415-1416
17. Goldstein J., Eisen G., Lewis B., Gralnek I., Fort J., Brown R., et al. Abnormal small bowel findings are common in healthy subjects screened for a multi-center, double blind, randomized, placebo controlled trial using capsule endoscopy [abstract]. Gastroenterology 124 (2003) A, 37
18. Laine L., Connors L., Reicen A., Hawkey C., Burgos-Vargas R., Schnitzer T., et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124 (2003) 288-292
19. Lisse J., Perlman M., Johansson G., Shoemaker J., Scjechtman J., Skalky C., et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 39 (2003) 539-546